NCT06654622 is a clinical trial in Colo-rectal Cancer, sponsored by City of Hope Medical Center.

Who is sponsoring NCT06654622?

NCT06654622 is sponsored by City of Hope Medical Center.

What condition does NCT06654622 study?

NCT06654622 studies Colo-rectal Cancer, Colorectal Cancer Recurrent.

Is NCT06654622 still recruiting?

NCT06654622 is currently completed. Last updated 13 March 2026.

Last reviewed 2026-03-13 · How we verify

NCT06654622

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Exosome-based Detection of Molecular Residual Disease in Stage II-III Colorectal Cancer

Completed Last updated 13 March 2026

What this trial tests

trial in Colo-rectal Cancer in 175 participants. Completed in 18 February 2026.

Timeline

1 April 2023

Primary endpoint
18 January 2026

18 February 2026

Quick facts

Lead sponsor	City of Hope Medical Center
Status	Completed
Study type	OBSERVATIONAL
Enrollment	175
Start date	1 April 2023
Primary completion	18 January 2026
Estimated completion	18 February 2026
Sites	1 location across United States

Conditions studied

Colo-rectal Cancer — all drugs for Colo-rectal Cancer →
Colorectal Cancer Recurrent — all drugs for Colorectal Cancer Recurrent →

Sponsor

City of Hope Medical Center

Who can join

18 and older, any sex, with Colo-rectal Cancer or Colorectal Cancer Recurrent. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study aims to establish an exosome-based liquid biopsy signature to detect molecular residual disease (MRD) in stage II-III colorectal cancer (CRC) patients. Identifying patients with MRD after surgery is crucial for selecting appropriate candidates for adjuvant chemotherapy (ACT), allowing for more personalized treatment approaches and potentially improving patient outcomes.

Publications & conference data

7 peer-reviewed publications reference this trial (live from Europe PMC):

Exosomes: innovative biomarkers leading the charge in non-invasive cancer diagnostics.
Li J, Wang A, Guo H, Zheng W, et al · · 2025 · cited 18× · PMID 40303340 · DOI 10.7150/thno.113650
Current trends in theranostic applications of extracellular vesicles in cancer.
Almasry Y, Mustafa F, Alfuwais M, AlNachef S, et al · · 2025 · cited 3× · PMID 40530018 · DOI 10.3389/fonc.2025.1592006
Multidimensional insights into exosomes in hepatocellular carcinoma: from genesis to clinical application.
Zhang X, Zhang C, Zhang Z, Zhang X. · · 2025 · cited 2× · PMID 40881702 · DOI 10.3389/fimmu.2025.1628573
Exosomal long noncoding RNAs and microRNAs in colorectal cancer.
Yen Y, Chu TY, Tseng RC. · · 2025 · cited 2× · PMID 40741613 · DOI 10.4103/tcmj.tcmj_62_25
Strategies, Challenges and Application Prospects for Exosome Engineering Modifications in Tumor Targeted Therapeutics.
Ge X, Shan S, Lu H, Wang W, et al · · 2026 · PMID 41878127 · DOI 10.2147/ijn.s572435
An exosome-based liquid biopsy to predict molecular residual disease for the identification of high-risk patients with stage II-III colorectal cancer: the CLEAR study.
Miyazaki K, Montcusí B, Morine Y, Okuno K, et al · · 2026 · PMID 41776599 · DOI 10.1186/s12943-026-02624-7
Insights into extracellular vesicle-based platforms on the way to cancer treatment.
Bagheri E, Aminyazdi E, Ramezani M, Mohammadi M, et al · · 2025 · PMID 41437080 · DOI 10.1186/s12967-025-07554-4

Verify or expand the search:

Other recruiting trials for Colo-rectal Cancer

Currently open trials in the same condition.

NCT06645015 — The AIDPRO-CRC Trial · NA · recruiting
NCT07145255 — Phase 1/2 Dose Finding, Safety and PK Study in Advanced Refractory Solid Tumors · Phase 1, PHASE2 · recruiting
NCT07085169 — Low-dose Trifluridine/Tipiracil With Bevacizumab in mCRC · Phase 2 · recruiting
NCT06880055 — Shield Post-Approval Study Protocol · recruiting
NCT06905925 — The Effect of the Training Program Given to Permanent Colostomy Patients on Self-efficacy · NA · recruiting

Other City of Hope Medical Center trials

Trials by the same sponsor.

NCT07365306 — Epcoritamab, Rituximab, Gemcitabine and Oxaliplatin (R-GemOx) as Salvage Therapy Before Autologous Stem Cell Transplant · Phase 2 · not yet recruiting
NCT07218692 — RP2 and Tivozanib for the Treatment of Metastatic Renal Cell Cancer After Progression on Immunotherapy · Phase 2 · not yet recruiting
NCT07363408 — Ivonescimab and ADG126, Alone, and in Combination With Leucovorin and Fluorouracil or FOLFIRI Regimen for the Treatment · Phase 1 · not yet recruiting
NCT07226102 — Virtual Mental Health Intervention to Address Fear of Progression for Women With High Risk or Stage III-IV Gynecologic o · NA · withdrawn
NCT07225855 — Geriatric Assessment and Management for Older Adults Undergoing Chemotherapy and Radiation Therapy for Head and Neck Can · NA · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT06654622 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by City of Hope Medical Center
Last refreshed: 13 March 2026

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06654622.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing